A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the CITE Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphi8a Negative CD19+ Acute Lymphobe

Administered By

Awarded By

Contributors

Start/End

  • September 11, 2020 - September 14, 2025